Fedratinib
Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research[1][2].
Product Specifications
CAS Number
[936091-26-8]
Product Name Alternative
TG-101348; SAR 302503
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; JAK
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/TG-101348.html
Purity
99.97
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=S(C1=CC=CC(NC2=NC(NC3=CC=C(C=C3)OCCN4CCCC4)=NC=C2C)=C1)(NC(C)(C)C)=O
Molecular Formula
C27H36N6O3S
Molecular Weight
524.68
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-10409/Fedratinib-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-10409/Fedratinib-SDS-MedChemExpress.pdf
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
JAK2
Citation 01
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Lentiviral human OVGP1 sgRNA gene knockout kit - Lentiviral human OVGP1 sgRNA gene knockout kit (100)
